Date: 2014-11-27
Type of information: Nomination
Compound: chief medical officer
Company: Quantum Genomics (France)
Therapeutic area: Cardiovascular diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On November 27, 2014, Quantum Genomics has appointed management Dr Olivier Madonna as chief medical officer of the company. Olivier Madonna will be in charge of the clinical developments of Quantum Genomics’ drug candidates and of the relations with regulatory authorities and drug safety agencies. He will manage, in collaboration with Pr Michel Azizi, Director of the clinical investigation Center at the European Hospital Georges Pompidou, the phase II clinical trial of QGC001 which has just been approved by the regulatory authorities in France. He will also lead the work on patients’ stratification and products positioning. Olivier Madonna has a broad international experience as head of medical departments of pharmaceutical and biotechnology companies. At Merck & Co, he acquired an in depth knowledge of the clinical development of antihypertensive drugs, such as Angiotensin-Converting Enzyme (ACE) inhibitors or Angiotensin II Receptor Blockers (ARBs).
He also was head of European Medical Affairs at Johnson & Johnson, in charge of several worldwide cardiovascular clinical trials and European registrations. As European Medical Director, he set up and managed several clinical trials in the hypertension and heart failure areas for the American-Australian group Resmed and for the Indian group Wockhardt. Olivier Madonna graduated as Medical Doctor from the University Claude Bernard in Lyon. He is a member of the French societies of Cardiology, Pharmacology, Nephrology and Hypertension. Former Intern then clinical head at Lyon Hospitals, he became attending physician in Nephrology at the Public Assistance - Paris Hospitals (APHP).
Financial terms:
Latest news:
Is general: Yes
